Tokyo Tape
Sign in
← Trans Genic Group

Annual report

2342.TEDINET S100YCRI
Period2025-04-01 → 2026-03-31
Filed2026-06-17
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 141
MetricValuePeriodScopeSource row
Revenue¥13.2bn2025-04-01 → 2026-03-31Cons.Net sales
Revenue¥13.0bn2024-04-01 → 2025-03-31Cons.Net sales
Revenue¥13.1bn2023-04-01 → 2024-03-31vCons.Net sales (5-year summary)
Revenue¥11.4bn2022-04-01 → 2023-03-31vCons.Net sales (5-year summary)
Revenue¥12.6bn2021-04-01 → 2022-03-31vCons.Net sales (5-year summary)
Operating income¥138m2025-04-01 → 2026-03-31Cons.Operating income
Operating income−¥260m2024-04-01 → 2025-03-31Cons.Operating income
Ordinary income¥118m2025-04-01 → 2026-03-31Cons.Ordinary income
Ordinary income−¥320m2024-04-01 → 2025-03-31Cons.Ordinary income
Ordinary income¥108m2023-04-01 → 2024-03-31vCons.Ordinary income loss (5-year summary)
Ordinary income¥199m2022-04-01 → 2023-03-31vCons.Ordinary income loss (5-year summary)
Ordinary income¥1.8bn2021-04-01 → 2022-03-31vCons.Ordinary income loss (5-year summary)
Profit before tax−¥207m2025-04-01 → 2026-03-31Cons.Income before income taxes
Profit before tax−¥676m2024-04-01 → 2025-03-31Cons.Income before income taxes
Net income (owners)−¥77m2025-04-01 → 2026-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)−¥1.1bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥4m2023-04-01 → 2024-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥410m2022-04-01 → 2023-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥1.9bn2021-04-01 → 2022-03-31vCons.Profit loss attributable to owners of parent (5-year summary)
Net income−¥97m2025-04-01 → 2026-03-31Cons.Profit loss
Net income−¥1.1bn2024-04-01 → 2025-03-31Cons.Profit loss
Total assets¥9.7bnat 2026-03-31Cons.Assets
Total assets¥9.6bnat 2025-03-31Cons.Assets
Total assets¥9.8bnat 2024-03-31vCons.Total assets (5-year summary)
Total assets¥10.7bnat 2023-03-31vCons.Total assets (5-year summary)
Total assets¥10.4bnat 2022-03-31vCons.Total assets (5-year summary)
Total liabilities¥4.9bnat 2026-03-31Cons.Liabilities
Total liabilities¥4.7bnat 2025-03-31Cons.Liabilities
Net assets / equity¥4.8bnat 2026-03-31Cons.Net assets
Net assets / equity¥4.9bnat 2025-03-31Cons.Net assets
Net assets / equity¥6.0bnat 2024-03-31vCons.Net assets
Net assets / equity¥6.1bnat 2023-03-31vCons.Net assets (5-year summary)
Net assets / equity¥6.6bnat 2022-03-31vCons.Net assets (5-year summary)
Cash and deposits¥2.1bnat 2026-03-31Cons.Cash and deposits
Cash and deposits¥2.6bnat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥2.1bnat 2026-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.5bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥2.5bnat 2024-03-31vCons.Cash and cash equivalents
Cash & equivalents¥3.5bnat 2023-03-31vCons.Cash and cash equivalents (5-year summary)
Cash & equivalents¥4.6bnat 2022-03-31vCons.Cash and cash equivalents (5-year summary)
Operating cash flow¥26m2025-04-01 → 2026-03-31Cons.Net cash provided by used in operating activities
Operating cash flow¥94m2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥392m2023-04-01 → 2024-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥1.4bn2022-04-01 → 2023-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥1.8bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in operating activities (5-year summary)
Investing cash flow¥51m2025-04-01 → 2026-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥288m2024-04-01 → 2025-03-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥281m2023-04-01 → 2024-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥216m2022-04-01 → 2023-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow¥982m2021-04-01 → 2022-03-31vCons.Net cash provided by used in investing activities (5-year summary)
Financing cash flow−¥518m2025-04-01 → 2026-03-31Cons.Net cash provided by used in financing activities
Financing cash flow¥265m2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥343m2023-04-01 → 2024-03-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥485m2022-04-01 → 2023-03-31vCons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥1.2bn2021-04-01 → 2022-03-31vCons.Net cash provided by used in financing activities (5-year summary)
EPS (basic)¥-4.642025-04-01 → 2026-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-65.512024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥0.242023-04-01 → 2024-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-24.322022-04-01 → 2023-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥109.522021-04-01 → 2022-03-31vCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥109.312021-04-01 → 2022-03-31vCons.Diluted earnings per share (5-year summary)
Net assets per share¥287.03at 2026-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥285.98at 2025-03-31Cons.Net assets per share (5-year summary)
Net assets per share¥355.19at 2024-03-31vCons.Net assets per share (5-year summary)
Net assets per share¥356.98at 2023-03-31vCons.Net assets per share (5-year summary)
Net assets per share¥388.43at 2022-03-31vCons.Net assets per share (5-year summary)
Equity ratio49.1%at 2026-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio49.7%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.1%at 2024-03-31vCons.Equity to asset ratio (5-year summary)
Equity ratio56.4%at 2023-03-31vCons.Equity to asset ratio (5-year summary)
Equity ratio62.6%at 2022-03-31vCons.Equity to asset ratio (5-year summary)
ROE0.1%2023-04-01 → 2024-03-31vCons.Rate of return on equity (5-year summary)
ROE32.8%2021-04-01 → 2022-03-31vCons.Rate of return on equity (5-year summary)
Employees227at 2026-03-31Cons.Number of employees
Employees241at 2025-03-31Cons.Number of employees
Employees236at 2024-03-31vCons.Number of employees
Employees236at 2023-03-31vCons.Number of employees
Employees213at 2022-03-31vCons.Number of employees
Revenue¥274m2025-04-01 → 2026-03-31StandaloneOperating revenue1
Revenue¥287m2024-04-01 → 2025-03-31StandaloneOperating revenue1
Revenue¥371m2023-04-01 → 2024-03-31vStandaloneNet sales (5-year summary)
Revenue¥397m2022-04-01 → 2023-03-31vStandaloneNet sales (5-year summary)
Revenue¥365m2021-04-01 → 2022-03-31vStandaloneNet sales (5-year summary)
Operating income¥2m2025-04-01 → 2026-03-31StandaloneOperating income
Operating income−¥20m2024-04-01 → 2025-03-31StandaloneOperating income
Ordinary income−¥22m2025-04-01 → 2026-03-31StandaloneOrdinary income
Ordinary income−¥37m2024-04-01 → 2025-03-31StandaloneOrdinary income
Ordinary income¥87m2023-04-01 → 2024-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥73m2022-04-01 → 2023-03-31vStandaloneOrdinary income loss (5-year summary)
Ordinary income¥76m2021-04-01 → 2022-03-31vStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥462m2025-04-01 → 2026-03-31StandaloneIncome before income taxes
Profit before tax−¥1.1bn2024-04-01 → 2025-03-31StandaloneIncome before income taxes
Net income−¥484m2025-04-01 → 2026-03-31StandaloneProfit loss
Net income−¥1.2bn2024-04-01 → 2025-03-31StandaloneProfit loss
Net income−¥662m2023-04-01 → 2024-03-31vStandaloneNet income loss (5-year summary)
Net income−¥104m2022-04-01 → 2023-03-31vStandaloneNet income loss (5-year summary)
Net income¥2.7bn2021-04-01 → 2022-03-31vStandaloneNet income loss (5-year summary)
Total assets¥5.5bnat 2026-03-31StandaloneAssets
Total assets¥6.4bnat 2025-03-31StandaloneAssets
Total assets¥6.9bnat 2024-03-31vStandaloneTotal assets (5-year summary)
Total assets¥8.0bnat 2023-03-31vStandaloneTotal assets (5-year summary)
Total assets¥7.6bnat 2022-03-31vStandaloneTotal assets (5-year summary)
Total liabilities¥1.3bnat 2026-03-31StandaloneLiabilities
Total liabilities¥1.8bnat 2025-03-31StandaloneLiabilities
Net assets / equity¥4.3bnat 2026-03-31StandaloneNet assets
Net assets / equity¥4.7bnat 2025-03-31StandaloneNet assets
Net assets / equity¥5.9bnat 2024-03-31vStandaloneNet assets
Net assets / equity¥6.7bnat 2023-03-31vStandaloneNet assets (5-year summary)
Net assets / equity¥6.8bnat 2022-03-31vStandaloneNet assets (5-year summary)
Cash and deposits¥459mat 2026-03-31StandaloneCash and deposits
Cash and deposits¥938mat 2025-03-31StandaloneCash and deposits
EPS (basic)¥-29.062025-04-01 → 2026-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-69.352024-04-01 → 2025-03-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-39.412023-04-01 → 2024-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-6.172022-04-01 → 2023-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥158.32021-04-01 → 2022-03-31vStandaloneBasic earnings loss per share (5-year summary)
EPS (diluted)¥1582021-04-01 → 2022-03-31vStandaloneDiluted earnings per share (5-year summary)
Dividend per share¥32023-04-01 → 2024-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥52022-04-01 → 2023-03-31vStandaloneDividend paid per share (5-year summary)
Dividend per share¥62021-04-01 → 2022-03-31vStandaloneDividend paid per share (5-year summary)
Net assets per share¥256.26at 2026-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥280.14at 2025-03-31StandaloneNet assets per share (5-year summary)
Net assets per share¥353.18at 2024-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥394.96at 2023-03-31vStandaloneNet assets per share (5-year summary)
Net assets per share¥406.51at 2022-03-31vStandaloneNet assets per share (5-year summary)
Equity ratio76.9%at 2026-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio72.4%at 2025-03-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio84.4%at 2024-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio83.4%at 2023-03-31vStandaloneEquity to asset ratio (5-year summary)
Equity ratio89.6%at 2022-03-31vStandaloneEquity to asset ratio (5-year summary)
ROE48.3%2021-04-01 → 2022-03-31vStandaloneRate of return on equity (5-year summary)
Shares issued16,999,141at 2026-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued16,999,141at 2025-03-31StandaloneTotal number of issued shares (5-year summary)
Shares issued16,999,141at 2024-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued16,999,141at 2023-03-31vStandaloneTotal number of issued shares (5-year summary)
Shares issued17,369,141at 2022-03-31vStandaloneTotal number of issued shares (5-year summary)
Employees6at 2026-03-31StandaloneNumber of employees
Employees5at 2025-03-31StandaloneNumber of employees
Employees6at 2024-03-31vStandaloneNumber of employees
Employees6at 2023-03-31vStandaloneNumber of employees
Employees7at 2022-03-31vStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 57
SegmentItemPeriodValue
Reconciling Itemsreconcilingcapex2025-04-01 → 2026-03-31¥1m
Reconciling Itemsreconcilingdepreciation2025-04-01 → 2026-03-31¥248,000
Reconciling Itemsreconcilingrevenue2025-04-01 → 2026-03-31−¥7m
Reconciling Itemsreconcilingrevenue intersegment2025-04-01 → 2026-03-31−¥7m
Reconciling Itemsreconcilingsegment assetsat 2026-03-31¥2.6bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2026-03-31−¥177m
Drug Discovery Support Businessreportable segmentcapex2025-04-01 → 2026-03-31¥61m
Drug Discovery Support Businessreportable segmentdepreciation2025-04-01 → 2026-03-31¥71m
Drug Discovery Support Businessreportable segmentemployeesat 2026-03-31132 pure
Drug Discovery Support Businessreportable segmentrevenue2025-04-01 → 2026-03-31¥2.3bn
Drug Discovery Support Businessreportable segmentrevenue external2025-04-01 → 2026-03-31¥2.3bn
Drug Discovery Support Businessreportable segmentrevenue intersegment2025-04-01 → 2026-03-31¥6m
Drug Discovery Support Businessreportable segmentsegment assetsat 2026-03-31¥3.0bn
Drug Discovery Support Businessreportable segmentsegment profit2025-04-01 → 2026-03-31−¥164m
Investments And Consulting Businessreportable segmentcapex2025-04-01 → 2026-03-31¥32m
Investments And Consulting Businessreportable segmentdepreciation2025-04-01 → 2026-03-31¥38m
Investments And Consulting Businessreportable segmentrevenue2025-04-01 → 2026-03-31¥10.9bn
Investments And Consulting Businessreportable segmentrevenue external2025-04-01 → 2026-03-31¥10.9bn
Investments And Consulting Businessreportable segmentrevenue intersegment2025-04-01 → 2026-03-31¥702,000
Investments And Consulting Businessreportable segmentsegment assetsat 2026-03-31¥4.1bn
Investments And Consulting Businessreportable segmentsegment profit2025-04-01 → 2026-03-31¥480m
TGBS Businessreportable segmentemployeesat 2026-03-3189 pure
—segment totalemployeesat 2026-03-31221 pure
Total Of Reportable Segments And Otherssegment totalcapex2025-04-01 → 2026-03-31¥93m
Total Of Reportable Segments And Otherssegment totaldepreciation2025-04-01 → 2026-03-31¥108m
Total Of Reportable Segments And Otherssegment totalrevenue2025-04-01 → 2026-03-31¥13.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2025-04-01 → 2026-03-31¥13.2bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2025-04-01 → 2026-03-31¥7m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2026-03-31¥7.1bn
Total Of Reportable Segments And Otherssegment totalsegment profit2025-04-01 → 2026-03-31¥315m
Reconciling Itemsreconcilingcapex2024-04-01 → 2025-03-31¥1m
Reconciling Itemsreconcilingdepreciation2024-04-01 → 2025-03-31¥1m
Reconciling Itemsreconcilingrevenue2024-04-01 → 2025-03-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2025-03-31−¥6m
Reconciling Itemsreconcilingsegment assetsat 2025-03-31¥2.8bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2025-03-31−¥210m
Drug Discovery Support Businessreportable segmentcapex2024-04-01 → 2025-03-31¥132m
Drug Discovery Support Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥102m
Drug Discovery Support Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥1.9bn
Drug Discovery Support Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥1.9bn
Drug Discovery Support Businessreportable segmentrevenue intersegment2024-04-01 → 2025-03-31¥6m
Drug Discovery Support Businessreportable segmentsegment assetsat 2025-03-31¥3.1bn
Drug Discovery Support Businessreportable segmentsegment profit2024-04-01 → 2025-03-31−¥488m
Investments And Consulting Businessreportable segmentcapex2024-04-01 → 2025-03-31¥135m
Investments And Consulting Businessreportable segmentdepreciation2024-04-01 → 2025-03-31¥36m
Investments And Consulting Businessreportable segmentrevenue2024-04-01 → 2025-03-31¥11.1bn
Investments And Consulting Businessreportable segmentrevenue external2024-04-01 → 2025-03-31¥11.1bn
Investments And Consulting Businessreportable segmentrevenue intersegment2024-04-01 → 2025-03-31¥438,000
Investments And Consulting Businessreportable segmentsegment assetsat 2025-03-31¥3.6bn
Investments And Consulting Businessreportable segmentsegment profit2024-04-01 → 2025-03-31¥439m
Total Of Reportable Segments And Otherssegment totalcapex2024-04-01 → 2025-03-31¥267m
Total Of Reportable Segments And Otherssegment totaldepreciation2024-04-01 → 2025-03-31¥139m
Total Of Reportable Segments And Otherssegment totalrevenue2024-04-01 → 2025-03-31¥13.0bn
Total Of Reportable Segments And Otherssegment totalrevenue external2024-04-01 → 2025-03-31¥13.0bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2024-04-01 → 2025-03-31¥6m
Total Of Reportable Segments And Otherssegment totalsegment assetsat 2025-03-31¥6.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2024-04-01 → 2025-03-31−¥50m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 1,436
ItemContextValueUnit
Subscription rights to sharesCurrentYearInstant_NonConsolidatedMember200000JPY
Net assetsPrior1YearInstant_NonConsolidatedMember4665394000JPY
Net assetsCurrentYearInstant_NonConsolidatedMember4267685000JPY
Liabilities and net assetsPrior1YearInstant_NonConsolidatedMember6441475000JPY
Liabilities and net assetsCurrentYearInstant_NonConsolidatedMember5546763000JPY
Operating revenue1Prior1YearDuration_NonConsolidatedMember287079000JPY
Operating revenue1CurrentYearDuration_NonConsolidatedMember274256000JPY
Operating expensesPrior1YearDuration_NonConsolidatedMember307052000JPY
Operating expensesCurrentYearDuration_NonConsolidatedMember272499000JPY
Operating incomePrior1YearDuration_NonConsolidatedMember-19972000JPY
Operating incomeCurrentYearDuration_NonConsolidatedMember1757000JPY
Interest and dividends income noiPrior1YearDuration_NonConsolidatedMember352000JPY
Interest and dividends income noiCurrentYearDuration_NonConsolidatedMember1138000JPY
Reversal of allowance for doubtful accounts noiPrior1YearDuration_NonConsolidatedMember－JPY
Reversal of allowance for doubtful accounts noiCurrentYearDuration_NonConsolidatedMember1982000JPY
Gain on forfeiture of unclaimed dividends noiPrior1YearDuration_NonConsolidatedMember682000JPY
Gain on forfeiture of unclaimed dividends noiCurrentYearDuration_NonConsolidatedMember1154000JPY
Other noiPrior1YearDuration_NonConsolidatedMember224000JPY
Other noiCurrentYearDuration_NonConsolidatedMember1236000JPY
Non operating incomePrior1YearDuration_NonConsolidatedMember1258000JPY
Non operating incomeCurrentYearDuration_NonConsolidatedMember5511000JPY
Interest expenses noePrior1YearDuration_NonConsolidatedMember11389000JPY
Interest expenses noeCurrentYearDuration_NonConsolidatedMember15868000JPY
Commission fee noePrior1YearDuration_NonConsolidatedMember6017000JPY
Commission fee noeCurrentYearDuration_NonConsolidatedMember13060000JPY
Other noePrior1YearDuration_NonConsolidatedMember814000JPY
Other noeCurrentYearDuration_NonConsolidatedMember618000JPY
Non operating expensesPrior1YearDuration_NonConsolidatedMember18221000JPY
Non operating expensesCurrentYearDuration_NonConsolidatedMember29546000JPY
Ordinary incomePrior1YearDuration_NonConsolidatedMember-36934000JPY
Ordinary incomeCurrentYearDuration_NonConsolidatedMember-22278000JPY
Gain on sales of investment securities eiPrior1YearDuration_NonConsolidatedMember－JPY
Gain on sales of investment securities eiCurrentYearDuration_NonConsolidatedMember137520000JPY
Extraordinary incomePrior1YearDuration_NonConsolidatedMember－JPY
Extraordinary incomeCurrentYearDuration_NonConsolidatedMember137520000JPY
Impairment loss elPrior1YearDuration_NonConsolidatedMember7024000JPY
Impairment loss elCurrentYearDuration_NonConsolidatedMember－JPY
Loss on valuation of investment securities elPrior1YearDuration_NonConsolidatedMember10671000JPY
Loss on valuation of investment securities elCurrentYearDuration_NonConsolidatedMember－JPY
Loss on valuation of stocks of subsidiaries and affiliates elPrior1YearDuration_NonConsolidatedMember91016000JPY
Loss on valuation of stocks of subsidiaries and affiliates elCurrentYearDuration_NonConsolidatedMember－JPY
Provision of allowance for doubtful accounts elPrior1YearDuration_NonConsolidatedMember1000000000JPY
Provision of allowance for doubtful accounts elCurrentYearDuration_NonConsolidatedMember543043000JPY
Special investigation costs etc elPrior1YearDuration_NonConsolidatedMember－JPY
Special investigation costs etc elCurrentYearDuration_NonConsolidatedMember34512000JPY
Other elPrior1YearDuration_NonConsolidatedMember713000JPY
Other elCurrentYearDuration_NonConsolidatedMember－JPY
Extraordinary lossPrior1YearDuration_NonConsolidatedMember1109426000JPY
Extraordinary lossCurrentYearDuration_NonConsolidatedMember577555000JPY
Income before income taxesPrior1YearDuration_NonConsolidatedMember-1146361000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 24 of 24 passed
balance sheet identityconsolidated 2025-03-31pass rounding
balance sheet identityconsolidated 2026-03-31pass rounding
balance sheet identitynon_consolidated 2025-03-31pass
balance sheet identitynon_consolidated 2026-03-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2026-03-31pass
statement vs summary · net assetsnon_consolidated 2024-03-31pass
statement vs summary · net assetsnon_consolidated 2025-03-31pass
statement vs summary · net assetsnon_consolidated 2026-03-31pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2025-03-31pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2026-03-31pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2025-03-31pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenueconsolidated 2024-04-01/2025-03-31pass
statement vs summary · revenueconsolidated 2025-04-01/2026-03-31pass
statement vs summary · revenuenon_consolidated 2024-04-01/2025-03-31pass
statement vs summary · revenuenon_consolidated 2025-04-01/2026-03-31pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2026-03-31pass
statement vs summary · total assetsnon_consolidated 2025-03-31pass
statement vs summary · total assetsnon_consolidated 2026-03-31pass